Spelling suggestions: "subject:"pbx"" "subject:"pb1""
1 |
TOWARDS A B-LYMPHOID MODEL OF E2A-PBX1-MEDIATED LEUKEMOGENESIS: EVALUATING THE IMPACT OF HEMATOPOIETIC CELL OF ORIGIN ON THE TRANSFORMATION PROPERTIES OF A LEUKEMOGENIC TRANSCRIPTION FACTORWoodcroft, MARK 03 September 2013 (has links)
The t(1;19) chromosomal translocation is present in 5% of acute lymphoblastic leukemia (ALL) cases and leads to expression of the oncogenic transcription factor, E2A-PBX1. Although t(1;19) is exclusively associated with pre-B ALL in clinical cases, murine models produce myeloid or T-lymphoid leukemias, which are not representative of the clinical disease. In this work, we have advanced progress towards the development an E2A-PBX1-driven experimental leukemia model. We initially determined that lineage-negative (lin-) hematopoietic progenitors expressing E2A-PBX1 expression fail to repopulate the B-lymphoid lineage when transplanted into irradiated recipient mice. Furthermore, E2A-PBX1 expressing, lin- fetal liver progenitors (FLPs) fail to differentiate into B-lymphocytes ex vivo. The majority of E2A-PBX1-expressing FLPs manifested an immature phenotype and displayed stem cell factor (SCF)-dependency and enhanced self-renewal. Additionally, these cells retained myeloid potential upon transplantation or stimulation with granulocyte macrophage colony-stimulating factor (GM-CSF). DNA binding was required for the differentiation block, suggesting that E2A-PBX1 target genes are incompatible with B-lineage specification. E2A-PBX1 FLPs had a stem cell like gene expression profile, including up-regulation of the leukemic transcription factors, Hoxa9 and Meis1. These findings explain why E2A-PBX1-driven bone marrow transplant models fail to generate B-lymphoid disease and suggest that future efforts in developing a model of E2A-PBX1-driven pre-B ALL leukemia should focus on expressing E2A-PBX1 subsequent to B-lymphoid commitment.
In an attempt to override the B-lymphoid differentiation block, we next expressed E2A-PBX1 in primary pre-B cells. E2A-PBX1 induced an apoptotic response in pre-B cells, which was consistent with previous observations. Since pre-B ALL induction requires secondary genetic events, we attempted to abrogate these E2A-PBX1-mediated effects by modulating expression of the Cdkn2a locus. Loss of Cdkn2a through deletion or Bmi1 overexpression failed to ameliorate the apoptotic response, suggesting that E2A-PBX1 mediated apoptosis occurs independently of Cdkn2a in murine pre-B cells. However, in the absence of Cdkn2a, co-expression of constitutively active MerTK or Ras attenuated the E2A-PBX1 mediated apoptosis.
Cumulatively, these results support the notion that t(1;19) occurs subsequent to B-lymphoid commitment and requires multiple secondary genetic lesions. Data presented in this thesis represents crucial initiating steps towards the development of a pre-B ALL model mediated by E2A-PBX1. / Thesis (Ph.D, Pathology & Molecular Medicine) -- Queen's University, 2013-09-03 00:09:29.299
|
2 |
Examining the effect of CBP on the E2A-PBX1 and HOXB4 interactionMenezes, Sean Christopher 29 September 2008 (has links)
The E2A-PBX1 fusion gene results from the t(1;19) chromosomal translocation that is found in 25% of pre-B-cell cases of acute lymphoblastic leukemia (ALL). The resulting encoded product contains the transactivation domains of E2A, a Class I basic helix-loop-helix transcription factor, and most of PBX1. PBX1 is a major cofactor for most members of the HOX family of homeodomain proteins and is necessary for regulating the essential role that HOX proteins play in development and tissue homeostasis. We have identified an interaction between the E2A-encoded portion of E2A-PBX1 and the CREB-binding domain (KIX) of the transcriptional coactivator CBP and demonstrated a requirement for this interaction in leukemia induction. Others have shown that HOX proteins and CBP also interact directly, with resulting inhibitory effects on the DNA-binding ability of HOX proteins and on the acetylation of substrate proteins by CBP. Several publications have also identified the interaction of HOX proteins with the PBX1 portion of E2A-PBX1 and the result is a potent transcriptional activator at PBX1/HOX target sequences. In an attempt to develop a molecular model for the induction of ALL by E2A-PBX1, we hypothesize that the addition of CBP interactive peptide elements encoded by E2A to PBX1 allows E2A-PBX1 to stabilize a ternary complex involving E2A-PBX1, HOX, and CBP resulting in the deregulated expression of critical PBX1 or HOX target genes. I demonstrate using in vitro protein-protein interactions that this ternary complex involving E2A-PBX1, HOXB4 (chosen as a representative member of the HOX family), and CBP does form. This direct interaction appears to reduce transcriptional activation by E2A-PBX1/HOXB4 heterodimers from PBX1/HOX enhancer elements. I also show that this suppression of transactivation appears to involve CBP antagonism of DNA binding by E2A-PBX1/HOXB4 heterodimers. My results are consistent with the idea that E2A-PBX1 contributes to ALL induction by promoting the redistribution of CBP away from DNA sites bound by E2A-PBX1/HOXB4 heterodimers and in favour of those sites bound by E2A-PBX1 homodimers. / Thesis (Master, Pathology & Molecular Medicine) -- Queen's University, 2008-09-29 13:57:25.324
|
3 |
Étude de la voie HOX-Flt3 dans les leucémies de type pré-B induites par E2A-Pbx1Vaisson, Gratianne 12 1900 (has links)
Introduction: Notre laboratoire a précédemment établi que Hoxa9 accélérait l’apparition de leucémie de type B induite par E2A-PBX1. Une analyse par qRT-PCR a montré que les niveaux d’ARN de Flt3, une cible de Hoxa9, étaient 32 fois plus élevés dans les leucémies Hoxa9/E2A-PBX1 par rapport que dans les leucémies E2A-PBX1. Il est important de noter que l’expression aberrante de Flt3 est retrouvée dans les leucémies ALL de type B et les AML. De plus, l’activation constitutive de Flt3 est associée à un faible pronostic. Nous avons posé l’hypothèse que la maintenance/ré-initiation des leucémies de type pré-B induites par E2A-Pbx1 est associée à la présence du récepteur Flt3.
Méthodes et Résultats: Premièrement, nous avons analysé par FACS la présence de Flt3 et mesuré l’expression de Flt3 par qRT-PCR des cellules E2A-PBX1 leucémiques pré-B. Nous avons montré que les cellules leucémiques E2A-PBX1 expriment l’ARNm du gène Flt3. Cependant, le récepteur n’était détectable à la surface cellulaire que dans des proportions variant de 0.3 à 28%. Deuxièmement, nous avons évalué le potentiel leucémique des fractions positive et négative pour Flt3. Toutes deux ont été capables de ré-initier la leucémie environ 20 jours après transplantation. Des analyses par FACS ont montré qu’une proportion de cellules leucémiques exprimaient Flt3, incluant même celles provenant de la fraction Flt3-. Troisièmement, une stratégie de perte de fonction de Flt3 par shARN a été mise en œuvre afin d’examiner le rôle de la voie de signalisation de Flt3 dans les cellules leucémiques E2A-PBX1. Pour ce faire, des cellules primaires leucémiques ont été infectées, soit par le shARN anti-Flt3 soit shARN contrôle, et transplantées dans des souris receveuses. Les cellules leucémiques contenant le shARN ont été capables de régénérer la leucémie. Cependant, une proportion des cellules exprimaient toujours Flt3, ce qui indique que l’efficacité des shARn n’était pas suffisante.
Conclusion et Perspectives: Nos shARN ne sont pas suffisamment efficaces sur les cellules leucémiques choisies. De ce fait, nous proposons d’utiliser des cellules leucémiques moins agressives tout en réalisant le même set-up expérimental. Des transplantations dans des receveurs KO Flt3-/- seraient également requises afin de réellement étudier l’impact de la voie de signalisation Flt3 dans la ré-initiation leucémique. / Introduction: Previous work in the laboratory have established that Hoxa9 accelerated the onset of E2A-PBX1 induced B cell leukaemia. qRT-PCR analysis showed that RNA levels of HOXA9 target Flt3 was 32-fold increased in Hoxa9/E2A-PBX1 compared to E2A-PBX1 leukaemia. It is important to note that aberrant expression of Flt3 is found in both B-ALL and AML. Moreover, constitutive activation of Flt3 is associated with a poor prognosis. We hypothesized that the acceleration of E2A-PBX1 B-ALL by Hoxa9 is caused through increased Flt3 signalling.
Methods and Results: First, to evaluate whether Flt3 signalling is functionally relevant for E2A-PBX1 induced leukaemia, Flt3 expression was analysed by FACS and qRT-PCR. So far, we showed that E2A-PBX1 B-ALL express FLT3 but the receptor was detected on a variable proportion of the cells, ranging from 0.3-28 %. Secondly, we evaluated the leukemic potential of Flt3 positive and negative fractions. Both reinitiate leukaemia around 20 days post-transplantation. Thirdly, a shRNA mediated knockdown strategy for Flt3 has been applied to test the relevance of Flt3 signalling on E2A-PBX1 leukemic cells. To test this, primary leukaemic cells were infected, either with the shRNA anti-Flt3 or the shRNA control, and transplanted into recipient mice. Unexpectedly, no difference was observed between the two groups of mice.
Conclusion and Relevance: Our shFLT3 is not efficient enough on the chosen leukemic cells. Therefore, we propose to apply the same set-up to a less aggressive leukaemia. Moreover, transplanting cells in Flt3-/- KO mice is required to really assess the impact of Flt3 signalling.
|
4 |
Novel mechanisms of transcriptional regulation by leukemia fusion proteinsGow, Chien-Hung, M.D. 17 October 2014 (has links)
No description available.
|
5 |
La collaboration entre l'oncogène E2A-PBX1 et Hoxa9 lors de l'induction de B-ALL implique l'activation de Flt3Hassawi, Mona 12 1900 (has links)
La protéine de fusion E2A-PBX1 induit une leucémie lymphoblastique aigüe des cellules B pédiatrique chez l’humain. E2A-PBX1 possède de puissantes propriétés de trans-activation et peut se lier à l’ADN ainsi qu’aux protéines homéotiques (HOX) via des domaines conservés dans sa portion PBX1, ce qui suggère qu’une dérégulation des gènes cibles de HOX/PBX1 contribue à la leucémogénèse. Précédemment, Bijl et al. (2008) ont démontré que certains gènes Hox collaborent de manière oncogénique avec E2A-PBX1, et que ces interactions sont cellules-spécifiques et varient en fonction du gène Hox impliqué. Une mutagénèse d’insertion provirale suggère et supporte la collaboration des gènes Hoxa et E2A-PBX1 lors de la leucémogénèse des cellules B. La présence de ces interactions dans les cellules B et leur implication dans l’induction des B-ALL est pertinente pour la compréhension de la maladie humaine, et reste encore mal comprise. Notre étude démontre qu’Hoxa9 confère un avantage prolifératif aux cellules B E2A-PBX1. Des expériences de transplantation à l’aide de cellules B E2A-PBX1/Hoxa9 positives isolées de chimères de moelle osseuse démontrent qu’Hoxa9 collabore avec E2A-PBX1 en contribuant à la transformation oncogénique des cellules, et qu’Hoxa9 seul n’induit aucune transformation. Une analyse par Q-RT-PCR nous a permis de démontrer une forte inhibition de gènes spécifiques aux cellules B dans les leucémies co-exprimant Hoxa9 et E2A-PBX1, en plus d’une activation de Flt3, suggérant une inhibition de la différenciation des cellules B accompagnée d’une augmentation de la prolifération. De plus, la surexpression de Hoxa9 dans des cellules leucémiques de souris transgéniques E2A-PBX1, confère aussi un avantage prolifératif aux cellules in vitro, qui semblent être influencé par une augmentation de l’expression de Flt3 et Pdgfδ. En conclusion, nous démontrons pour la première fois à l’aide d’un modèle murin qu’Hoxa9 collabore avec E2A-PBX1 lors de la transformation oncogénique des cellules B et que la signalisation via Flt3 est impliquée, ce qui est potentiellement pertinent pour la maladie humaine. / The fusion protein E2A-PBX1 induces pediatric B cell leukemia in human. It has strong transactivating properties and can bind to DNA and homeobox (HOX) proteins through conserved domains in the PBX1 portion, suggesting that deregulation of HOX/PBX target genes contribute to leukemogenesis. Previously, we reported oncogenic interactions between Hox genes and E2A-PBX1, which are dependent on cell type as well as on the particular Hox member. A proviral insertional mutagenesis screen provided support for collaboration between Hoxa genes and E2A-PBX1 in B cell leukemogenesis. Whether these interactions occur in B cells and lead to B-ALL, relevant for human disease is still not clear. Here we report that Hoxa9 confers a proliferative advantage to E2A-PBX1 B cells. Transplantation experiments with E2APBX1/Hoxa9 positive B cells isolated from bone marrow (BM) chimeras showed that Hoxa9 interacts with E2A-PBX1 contributing to the oncogenic transformation of B cells, but is unable to transform B cells alone. Q-RT-PCR analysis demonstrated a strong repression of B cell specific genes in leukemias co-overexpressing Hoxa9 and E2A-PBX1 in addition to Flt3 activation, indicating inhibition of B cell differentiation in combination with enhanced proliferation. Overexpression of Hoxa9 in E2A-PBX1 mouse leukemic B cells also resulted in a growth advantage in vitro, likely mediated by the enhanced expression of Flt3 and Pdgfδ. In conclusion we show for the first time that Hoxa9 collaborates with E2A-PBX1 in the oncogenic transformation of B cells in a mouse model that involves Flt3 signaling, which is potentially relevant to human disease.
|
Page generated in 0.0347 seconds